Machine learning model opens door to real-time detection of cell therapy contamination
Researchers at the Massachusetts Institute of Technology’s Singapore site have developed a new way to detect adventitious microbial contamination in mesenchymal stromal cell cultures. By using machine learning to predict if a culture is contaminated in near real-time, the approach could enable testing to take place during the production of cell therapy products. Read More
Beta cell gene deletion stops type 1 diabetes in mice, suggesting new way to prevent disease
Deleting a proinflammatory gene in the beta cells of pre-diabetic mice stops the development of type 1 diabetes, pointing to a potential way to prevent the condition, according to a study published on June 28 in the journal Cell Reports. Read More
Harnessing the power of chromatin science to target disease
ScienceBoard.net spoke with Martis Cowles, PhD, chief business officer at EpiCypher at the 2022 Biotechnology Innovation Organization International Convention about EpiCypher’s efforts to harness the power of chromatin science and provide insights into the chromatin regulatory system, which plays a critical role in many disease processes. Read More
Machine Bio seeks to fundamentally change how biotechs make protein
Protein purification is one of the biggest bottlenecks for biotechnology companies. However, startup Machine Bio is developing a next-generation protein synthesis platform that can produce pure protein from DNA in hours, minutes, or continuously using a single step process. Founders David Marash and Jack Fernandes spoke with ScienceBoard.net at the 2022 Biotechnology Innovation Organization International Convention. Read More
How one CDMO is navigating the global supply chain disruption
The COVID-19 pandemic has disrupted supply chains and production schedules around the world, forcing contract development and manufacturing organizations (CDMOs) to adapt. In a video interview at the 2022 Biotechnology Innovation Organization International Convention, Federico Pollano of Rentschler Biopharma discussed how the company is navigating the worldwide supply chain disruption. Read More
NIH seeks industry partners for technology transfer
The National Institutes of Health (NIH) is the world’s largest public funder of biomedical research. ScienceBoard.net spoke with Michael Salgaller of the National Cancer Institute at the 2022 Biotechnology Innovation Organization International Convention about NIH’s technology transfer professionals who work with its scientist inventors to find commercial partners to take their inventions to market. Read More
Estonia’s ambitious plans to grow its biotech industry
The Baltic state of Estonia's biotech industry is expected to grow tenfold this decade and offers significant opportunities for Estonian companies. ScienceBoard.net spoke with Andres Sutt, Estonia’s minister of entrepreneurship and information technology, at the 2022 Biotechnology Innovation Organization International Convention in San Diego about the country’s ambitious plans to grow its biotech industry. Read More
Fauna Bio leverages animal genomics, hibernation biology to target human diseases
Biotech company Fauna Bio is leveraging animal genomics and hibernation biology to develop novel translational therapeutics for disease prevention and reduce the impact of age-related diseases in humans. ScienceBoard.net spoke with co-founder and CEO Ashley Zehnder about the intersection of animal genomics, hibernation biology, and human diseases. Read More
Using the power of plants to develop novel biopharmaceuticals
Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines. ScienceBoard.net spoke with CEO Tom Isett at the 2022 Biotechnology Innovation Organization International Convention about the company’s technology, programs, and more. Read More
Apeiron Biologics' spinout invIOs targets solid tumors with novel cell therapy platform
Apeiron Biologics' spinout invIOs has a proprietary cell therapy platform for the modulation of intracellular immuno-oncology targets that enables rapid treatment of cancer patients using their own immune cells with short out-of-body time in out-patient settings. ScienceBoard.net spoke with invIOs’ CEO Peter Llewellyn-Davies at the 2022 Biotechnology Innovation Organization International Convention in San Diego. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
